Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5
BOSTON , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Tuesday, March 5 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and
View HTML
Toggle Summary Ziopharm Oncology CEO to Present at the CAR-TCR Summit Europe
BOSTON , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that Chief Executive Officer Laurence Cooper , M.D., Ph.D, is scheduled to present and participate in a panel discussion on Feb. 26 at the CAR-TCR Summit Europe in London .
View HTML
Toggle Summary Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial
-- Substudy promptly accrued 36 patients in less than six months, with majority of newly enrolled patients receiving low-dose steroids -- BOSTON , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that it rapidly completed enrollment and treated a total of 36
View HTML
Toggle Summary Ziopharm Oncology Presenting at the 37th Annual J.P. Morgan Healthcare Conference
BOSTON, MA, January 10, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) Laurence Cooper, M.D., Ph.D., Chief Executive Officer, today is presenting at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco at 9 a.m. PT/12 noon ET.
View HTML
Toggle Summary Ziopharm Oncology Posts Letter to Stockholders
BOSTON , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today posted and released the following letter: Dear Fellow Stockholders, With the 37 th Annual J.P. Morgan Healthcare Conference upon us, we wanted to communicate directly with our shareholders.
View HTML
Toggle Summary Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets
BOSTON , Dec. 27, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today responded to the recent decline in the Company’s stock price, which accelerated greatly on December 26, 2018 , the same day that the broader market and all indexes were up significantly.
View HTML
Toggle Summary Ziopharm Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
BOSTON , Dec. 21, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 , at 9 a.m. PST .
View HTML
Toggle Summary Ziopharm Oncology and TriArm Therapeutics Establish Joint Venture to Develop and Commercialize Sleeping Beauty CAR T in China, Taiwan and Korea
-- Joint venture to operate as Eden BioCell -- -- TriArm Therapeutics, a Panacea Venture Healthcare company, to fund Eden BioCell with up to $35M -- -- Ziopharm to license rights of third-generation Sleeping Beauty CD19-specific CAR-T cell therapies to Eden BioCell -- -- Eden BioCell to be owned
View HTML
Toggle Summary Ziopharm Oncology Promotes Dr. David Mauney to President
BOSTON , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that David Mauney , M.D., has been promoted to President effective immediately. Dr. Mauney, who joined Ziopharm in 2017 as Executive Vice President and Chief Business Officer, will continue to report
View HTML
Toggle Summary Ziopharm Oncology Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial Presented at Annual Meeting of the Society for Neuro-Oncology
Ad-RTS-hIL-12 plus 20mg veledimex (Controlled IL-12) determined to be preferred dosing with low-dose steroids to treat adult patients with recurrent glioblastoma Median overall survival for Ad-RTS-hIL-12 plus veledimex in patients receiving low-dose steroids is 17.8 months Controlled IL-12
View HTML